Zero Homes | $16,800,000 | (Feb 19, 2026)
Rainfall Health | $15,000,000 | (Feb 19, 2026)
inKind | $450,000,000 | (Feb 19, 2026)
Certified by Founder
Lodge
ImpriMed, Inc.
start up
United States
- Mountain View, California
- 20/12/2023
- Series A
- $23,000,000
ImpriMed provides cutting-edge personalized medicine easily accessible for pets with blood cancer diseases. ImpriMed’s key product, Personalized Prediction Profile, has been used by board-certified veterinary oncologists, helping over 5,000 dogs with lymphoma and leukemia. With ImpriMed’s services, veterinarians make their treatment decisions quickly and with confidence. This innovative approach to cancer care has been published in a scientific journal and presented at major conferences and is supported by over 350 veterinary oncologists at 200+ specialty hospitals in the US.
- Industry Biotechnology Research
- Website https://www.imprimedicine.com/
- LinkedIn https://www.linkedin.com/company/imprimed-inc/about/
Sift Biosciences | $3,700,000 | (Feb 19, 2026)
Avantos.ai | $25,000,000 | (Feb 19, 2026)
Korsana Biosciences | $175,000,000 | (Feb 19, 2026)
Vervesemi | $10,000,000 | (Feb 19, 2026)
Efficient Computer | $60,000,000 | (Feb 19, 2026)
DG Matrix | $60,000,000 | (Feb 19, 2026)
Synchrony Medical | $5,000,000 | (Feb 19, 2026)
Dataro | $14,280,000 | (Feb 18, 2026)
The Compression Company | $3,400,000 | (Feb 18, 2026)